The University of Texas Southwestern Medical Center, Department of Radiology, 5323 Harry Hines Blvd, Dallas, Texas 75390 USA.
Eur J Radiol. 2020 Dec;133:109365. doi: 10.1016/j.ejrad.2020.109365. Epub 2020 Oct 26.
To compare the outcomes of microcalcifications recalled on full-field digital (FFDM) and FFDM and combined tomosynthesis (Combo) to synthetic (SM) screening mammograms.
We reviewed medical records, radiology, and pathology reports of all patients found to have abnormal calcifications requiring further evaluation on mammography screening at our institution between 11/1/2016-11/1/2018 and collected patient demographics, calcification morphology and distribution, and mammography technique (SM, FFDM, or Combo). We used biopsy pathology or at least 1-year imaging follow-up to establish overall diagnostic outcome (benign or malignant). Fisher's exact test was used to compare validation rates at diagnostic work-up, BI-RADS category, and final outcome of calcifications identified on each screening technique. T-test was used for continuous variables.
Of 699 calcifications in 596 women recalled, 176 (30%) of 596 were from SM and 420 (70%) FFDM/Combo. There was a significantly higher rate of calcifications unvalidated at diagnostic work-up for SM compared to FFDM/Combo (0.8% vs. 10%, p < 0.0001). SM calcifications were more likely to receive BI-RADS 2/3 at diagnostic work-up compared to FFDM/Combo ones (55% vs. 42%, p = 0.003). Of 346 (49%) calcifications that underwent biopsy, 88 (25%) were malignant (36% of SM vs. 22% of FFDM/Combo, OR:0.5 [95% CI: 0.3, 0.8] p = 0.01). Of 622 lesions with established diagnostic outcome, there was no difference between having an overall benign or malignant outcome between SM and FFDM/Combo (17% vs. 13%, OR: 0.8 [95% Cl: 0.5, 1.2] p = 0.27).
Synthetic tomosynthesis screening results in a higher rate of false positive and unvalidated calcification recalls compared to FFDM/Combo.
比较全数字化乳腺摄影术(FFDM)和 FFDM 与合成(SM)筛查乳房 X 光检查中召回的微钙化的结果。
我们回顾了 2016 年 11 月 1 日至 2018 年 11 月 1 日期间,在我院接受异常钙化需要进一步评估的所有患者的病历、放射学和病理学报告,并收集了患者的人口统计学资料、钙化形态和分布,以及乳房 X 光摄影技术(SM、FFDM 或 Combo)。我们使用活检病理或至少 1 年的影像学随访来确定整体诊断结果(良性或恶性)。Fisher 精确检验用于比较每种筛查技术中诊断性检查、BI-RADS 分类和钙化最终结果的验证率。连续变量采用 t 检验。
在召回的 596 名女性的 699 个钙化中,176 个(30%)来自 SM,420 个(70%)来自 FFDM/Combo。SM 钙化在诊断性检查中未得到验证的比例明显高于 FFDM/Combo(0.8%比 10%,p<0.0001)。SM 钙化在诊断性检查中更有可能被 BI-RADS 2/3 分类,而 FFDM/Combo 则不然(55%比 42%,p=0.003)。在 346 个(49%)接受活检的钙化中,有 88 个(25%)为恶性(SM 中为 36%,FFDM/Combo 中为 22%,OR:0.5[95%CI:0.3,0.8],p=0.01)。在 622 个有明确诊断结果的病变中,SM 和 FFDM/Combo 之间的总体良性或恶性结果没有差异(17%比 13%,OR:0.8[95%Cl:0.5,1.2],p=0.27)。
与 FFDM/Combo 相比,合成断层合成术筛查导致更高的假阳性和未验证的钙化召回率。